Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 78Neoplasm Metastasis 16Neoplasms 9Breast Neoplasms, Male 9Brain Neoplasms 6Urinary Bladder Neoplasms 5Ovarian Neoplasms 5Head and Neck Neoplasms 4Colorectal Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Lung Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Ovarian Epithelial 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Pancreatic Neoplasms 2Neuroma, Acoustic 2Neurofibromatosis 2 2Inflammatory Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Ductal, Breast 2Salivary Gland Neoplasms 1Recurrence 1Prolactinoma 1Pituitary Neoplasms 1Patient Compliance 1Neuroectodermal Tumors, Primitive 1

Interventions

pyrotinib 1pertuzumab 1Vinorelbine 1Trastuzumab 1Lapatinib 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2 Positive Breast Cancer × Lapatinib × Clear all
NCT02362958 2020-07-15

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Sun Yat-sen University

Phase 2 Completed
159 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡